Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
| Image |  |
|---|---|
| Description | scientific article published on September 2009 |
| Author/s |
author: Saengsuree Jootar Nelson Hamerschlak David Dejardin Jerzy Hołowiecki Vincent Levy |
| Publication date | September 1, 2009 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |